|
Title
|
|
|
|
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma : experience from a global expanded access program
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Background Avelumab, a human anti-programmed death-ligand 1 immunoglobulin G1 monoclonal antibody, showed favorable efficacy and safety in patients with metastatic Merkel cell carcinoma (mMCC) in the phase II JAVELIN Merkel 200 trial, leading to approval in multiple countries. We describe real-world experience with avelumab in patients with mMCC from an expanded access program. Methods Eligible patients had mMCC and progressive disease during or after chemotherapy or were ineligible for chemotherapy or clinical trial participation. Patients received an initial 3-month supply of avelumab (administered as 10mg/kg intravenously every 2 weeks until progressive disease or unacceptable toxicity); resupply was allowed following complete response, partial response, stable disease, or clinical benefit per physician assessment. Results Between December 15, 2015, and March 4, 2019, 558 of 620 requests from 38 countries were medically approved, and 494 patients received avelumab. Among 240 evaluable patients, the objective response rate was 46.7% (complete response in 22.9%, including 3 of 16 potentially immunocompromised patients), and the disease control rate was 71.2%. The median duration of treatment in evaluable patients with response was 7.9 months (range, 1.0-41.7) overall and 5.2 months (range, 3.0-13.9) in immunocompromised patients. No new safety signals were identified. The expanded access program closed for new requests on December 31, 2018, as required after regulatory approval; benefitting patients continued to receive avelumab. Conclusions The avelumab expanded access program for patients with mMCC demonstrated efficacy and safety in a real-world setting, consistent with the results from JAVELIN Merkel 200, and provided a treatment for patients with limited options. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Journal for immunotherapy of cancer
| |
|
Publication
|
|
|
|
2020
| |
|
DOI
|
|
|
|
10.1136/JITC-2019-000313
| |
|
Volume/pages
|
|
|
|
8
:1
(2020)
, 6 p.
| |
|
Article Reference
|
|
|
|
e000313
| |
|
ISI
|
|
|
|
000588327800016
| |
|
Pubmed ID
|
|
|
|
32269140
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|